Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Usana Health SciencesSTU:USJ +3.78%67 ROE % is 5.20% as of Mar. 2026, which is 77% below its 10-year median of 22.62. GuruFocus rates STU:USJ with a GF Score™ of 67/100 and a GF Value™ of €35.51 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,924 Consumer Packaged Goods companies, Usana Health Sciences ranks worse than 69.65% on this metric.
The historical rank and industry rank for Usana Health Sciences's ROE % or its related term are showing as below:
STU:USJ'
s ROE % Range Over the Past 10 Years
Min: 1.56 Med: 22.62 Max: 33.47
Current: 1.56
During the past 13 years, Usana Health Sciences's highest ROE % was 33.47%. The lowest was 1.56%. And the median was 22.62%.
STU:USJ's ROE % is ranked worse than 69.65% of 1924
companies
in the Consumer Packaged Goods industry
Industry Median: 6.785
vs STU:USJ: 1.56
Usana Health Sciences (STU:USJ) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Usana Health Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Usana Health Sciences ROE % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's ROE % distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Usana Health Sciences (STU:USJ) has a ROE % of 5.20% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Usana Health Sciences and its competitors. This is 77% below median its historical median of 22.62. Over the past decade, Usana Health Sciences' ROE % has ranged from 1.56 to 33.47. According to the industry distribution chart, Usana Health Sciences ranks #1340 out of 1924 companies in the Consumer Packaged Goods industry, placing it in the top 69.6%.
Is Usana Health Sciences' ROE % too high?
Usana Health Sciences' current ROE % of 5.20% is 77% below median its 10-year median of 22.62. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 33.47. The Consumer Packaged Goods industry median ROE % is 6.79. Usana Health Sciences' value of 5.20% is 23.4% below this industry median. Based on the distribution chart, Usana Health Sciences ranks #1340 out of 1924 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Usana Health Sciences has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Usana Health Sciences' ROE % compare to NATR and ENHA?
According to the Consumer Packaged Goods industry distribution chart, Usana Health Sciences ranks #1340 out of 1924 companies for ROE %. This places Usana Health Sciences in the lower half of its industry. The industry median ROE % is 6.79. Usana Health Sciences' value of 5.20% is 23.4% below this benchmark. Historically, Usana Health Sciences' own ROE % has ranged from 1.56 to 33.47 over the past decade. While the company's 10-year median is 22.62 vs. the industry median of 6.79, Usana Health Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Consumer Packaged Goods company?
The median ROE % among Consumer Packaged Goods companies is 6.79, based on 1,924 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Usana Health Sciences's current ROE % of 5.20% is 23.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Usana Health Sciences and its competitors. For the Consumer Packaged Goods industry, the median ROE % is 6.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Usana Health Sciences's current ROE % is 5.20%, which is 77% below median its own 10-year median of 22.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Usana Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Usana Health Sciences (STU:USJ) is currently considered Possible Value Trap. The stock's GF Value™ is €35.51, compared to a current price of €19.20 — trading 45.9% below its estimated fair value. The current ROE % is 5.20%, which is 77% below median its 10-year median of 22.62 and 23.4% below the Consumer Packaged Goods industry median of 6.79. Usana Health Sciences' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Usana Health Sciences (STU:USJ), the current ROE % is 5.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Usana Health Sciences (STU:USJ) Overvalued in 2026?
Based on GuruFocus' analysis, Usana Health Sciences stock appears to be undervalued.
The current stock price of €19.20 is trading 45.9% below its estimated GF Value™ of €35.51.
GuruFocus considers Usana Health Sciences to be Possible Value Trap.
Key valuation signals for STU:USJ:
ROE %: 5.20% (77% below median its 10-year median of 22.62)
GF Value™: €35.51 vs. price of €19.20 (45.9% below fair value)
Industry Position: 23.4% below the Consumer Packaged Goods median (#1340 of 1924)
No single metric tells the full story. See the STU:USJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
67GF Score
Get the complete analysis for STU:USJ
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:USJ has been successfully added to your 
